NasdaqGS - Delayed Quote • USD
Alnylam Pharmaceuticals, Inc. (ALNY)
At close: May 10 at 4:00 PM EDT
After hours: May 10 at 7:05 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 21 | 21 | 22 | 22 |
| Avg. Estimate | -1.11 | -1.06 | -3.6 | -1.87 |
| Low Estimate | -1.57 | -1.69 | -5.56 | -4.38 |
| High Estimate | -0.36 | -0.31 | -1.07 | 2.31 |
| Year Ago EPS | -2.21 | 1.15 | -3.52 | -3.6 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 22 | 21 | 26 | 26 |
| Avg. Estimate | 442.73M | 459.44M | 1.87B | 2.3B |
| Low Estimate | 415M | 441M | 1.73B | 1.48B |
| High Estimate | 485M | 495.5M | 2B | 2.97B |
| Year Ago Sales | 318.75M | 750.53M | 1.83B | 1.87B |
| Sales Growth (year/est) | 38.90% | -38.80% | 2.30% | 22.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.37 | -1.34 | -1.32 | -1.18 |
| EPS Actual | -2.21 | 1.15 | -1.1 | -0.52 |
| Difference | -0.84 | 2.49 | 0.22 | 0.66 |
| Surprise % | -61.30% | 185.80% | 16.70% | 55.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.11 | -1.06 | -3.6 | -1.87 |
| 7 Days Ago | -1.06 | -1.05 | -3.95 | -1.75 |
| 30 Days Ago | -1.04 | -1.1 | -4.1 | -1.76 |
| 60 Days Ago | -1.03 | -1.1 | -4.18 | -1.77 |
| 90 Days Ago | -1.21 | -1.32 | -4.2 | -1.04 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 6 | 5 | 12 | 4 |
| Up Last 30 Days | 10 | 11 | 23 | 10 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 8 | 9 | 3 | 9 |
Growth Estimates
| CURRENCY IN USD | ALNY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 49.80% | -- | -- | 7.30% |
| Next Qtr. | -192.20% | -- | -- | 10.80% |
| Current Year | -2.30% | -- | -- | 4.60% |
| Next Year | 48.10% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -177.50% | -- | -- | 10.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/7/2024 |
| Maintains | Chardan Capital: Buy to Buy | 5/3/2024 |
| Reiterates | Needham: Buy to Buy | 5/2/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 3/27/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/5/2024 |
| Maintains | Cantor Fitzgerald: Neutral to Neutral | 2/23/2024 |
Related Tickers
IONS Ionis Pharmaceuticals, Inc.
39.08
-0.99%
ARWR Arrowhead Pharmaceuticals, Inc.
22.08
-10.68%
BMRN BioMarin Pharmaceutical Inc.
81.03
-0.84%
ARGX argenx SE
374.63
-2.07%
BGNE BeiGene, Ltd.
161.13
-4.45%
INCY Incyte Corporation
53.06
-0.82%
BBIO BridgeBio Pharma, Inc.
29.10
+1.29%
LEGN Legend Biotech Corporation
43.24
-5.01%
APLS Apellis Pharmaceuticals, Inc.
41.99
-1.25%
KRYS Krystal Biotech, Inc.
154.76
-2.50%